IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/005931

International Filing Date : 02 June 2004 (02.06.2004)

Priority Date(s) Claimed : 25 June 2003 (25.06.2003)

Applicant(s) (DO/EO/US) : Philippe GUEDAT, et al.

Title: THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes		Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:					
		within three months of the filing date of a national application other than a CPA under § 1.53(d);					
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR					
		before the mailing of a first substantive office action (including after filing of an RCE).					
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods lied in 37 C.F.R. § 1.97(b), but before the mailing date of:					
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and					

1

DOCKET NO.: MERCK-3095

10/561989 IAP9 Rec'd PCT/PTO 23 DEC 2005

		is accompanied by:						
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR					
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).					
		der 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing e of the following actions which have not been withdrawn:						
		a final	action under 37 C.F.R. § 1.113;					
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);					
		OR a r	notice of allowance under 37 C.F.R. § 1.311;					
	AND i	is filed o	on or before payment of the issue fee; AND is accompanied by:					
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).					
Staten	nents Ur	nder 37	C.F.R. 1.97(e)					
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or					
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.					
Cited	Materia	<u>ls</u>						
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).					
	\boxtimes		s of materials listed but not attached were cited in an international search dated <u>September 24, 2004</u> .					
		Not re	quired by 37 CFR § 1.98.					
		Copies	Copies of the materials listed are attached (except for the foregoing).					

Non-Eng	lish Language References
×	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art O = non-written disclosure
	P = intercalated document
	T = document cited to understand the theory or principle underlying the invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
	Translation of other relevant information on foreign search report
Other Inf	<u>Cormation</u>
Payment	of Fees Due (If Any):
	check for \$ covering the fee identified above is attached.
P	lease charge to Deposit Account No. 13-3402 \$ for the fee identified above.

10/561989 IAP9 Rec'd PCT/PTO 23 DEC 2005

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3095

Date: December 23, 2005

AJZ:ssr

DOCKET NO.: MERCK-3095

10/561989

1479 Rec'd POTAPTO 23 DEC 2005

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	e for form 1449A/PT()		Complete if Known		
				Application Number	USNP of PCT/EP2004/005931	
INFO	RMATION	DISC	LOSURE	Filing Date	02 June 2004 (02.06.2004)	
STAT	FEMENT B	Y API	PLICANT	First Named Inventor	Philippe GUEDAT, et al.	
				Group Art Unit	unknown	
	(use as many she	eets as ne	ecessary)	Examiner Name	unknown	
Sheet	1	of	1	Attorney Docket Number MERCK-3095		

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.¹	U.S. Patent Docun	nent Kind Code ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	001	2004/034028	A1	GUEVEL, ET AL.	02-19-2004			
					10.			

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
	002	wo	03/047575	Α	DAUGAN, ET AL.	06-12-2003		
	003	FR	2 816 940	Α	LIPHA	05-24-2002		001
				<u> </u>				
	-							

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.